Radiation Oncology

HR+

Questions discussed in this category

What are your top takeaways in Medical Oncology from SABCS 2025?

6 Answers available

What are your top takeaways in Medical Oncology from SABCS 2024?

13 Answers available

What are your top takeaways in Breast Cancer from ESMO 2024?

4 Answers available

Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?

Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib...

2 Answers available

Would you treat a Stage I ER/PR positive HER2 negative breast cancer differently if it is associated with Lynch syndrome?

3 Answers available

How would you treat a patient with ER/PR positive breast cancer with a single site of bone metastasis?

Is your approach different for oligometastatic versus oligoprogressive disease? If there is concurrent locally advanced disease, would you treat simul...

2 Answers available

Papers discussed in this category

J Clin Oncol, 2022 Jan 07

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).

Ann Surg,

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Front Oncol, 2020 May 29

Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants.

Cancer Cell Int, 2021 May 17

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization.

The New England journal of medicine, 2024 Sep 15

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Nature medicine, 2024 Sep 13

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

The New England journal of medicine, 2024 Sep 15

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 06

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

The New England journal of medicine, 2024 Dec 11

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

JAMA, 2025 Dec 12

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

Lancet, 2024 Apr 27

3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 12

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Related Topics in Radiation Oncology